Conestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

Conestoga Capital Advisors LLC lowered its stake in Alpha Teknova, Inc. (NASDAQ:TKNO) by 21.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 192,274 shares of the company’s stock after selling 52,070 shares during the period. Conestoga Capital Advisors LLC’s holdings in Alpha Teknova were worth $998,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of TKNO. JPMorgan Chase & Co. lifted its holdings in shares of Alpha Teknova by 622.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,400 shares of the company’s stock worth $37,000 after acquiring an additional 3,791 shares during the period. Mount Lucas Management LP bought a new stake in Alpha Teknova during the fourth quarter worth $75,000. Two Sigma Investments LP increased its stake in shares of Alpha Teknova by 46.2% in the 4th quarter. Two Sigma Investments LP now owns 15,148 shares of the company’s stock valued at $126,000 after purchasing an additional 4,789 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of Alpha Teknova by 14.3% during the 4th quarter. NewEdge Advisors LLC now owns 15,632 shares of the company’s stock worth $131,000 after buying an additional 1,953 shares during the last quarter. Finally, Barclays PLC acquired a new position in Alpha Teknova during the fourth quarter worth about $132,000. Institutional investors own 13.81% of the company’s stock.

Alpha Teknova Stock Performance

Shares of TKNO stock opened at $5.48 on Tuesday. The stock’s fifty day simple moving average is $6.11 and its 200 day simple moving average is $6.96. The firm has a market capitalization of $292.86 million, a P/E ratio of -7.41 and a beta of 0.40. Alpha Teknova, Inc. has a twelve month low of $1.16 and a twelve month high of $10.37. The company has a quick ratio of 3.94, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Alpha Teknova (NASDAQ:TKNO) last announced its earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The business had revenue of $9.60 million during the quarter, compared to the consensus estimate of $9.41 million. As a group, sell-side analysts predict that Alpha Teknova, Inc. will post -0.58 EPS for the current fiscal year.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.